AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 1 filers reported holding AIMMUNE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q3 2020 | $1,000 | -97.7% | 15 | -99.4% | 0.00% | -100.0% |
| Q2 2020 | $44,000 | +2.3% | 2,660 | -14.9% | 0.00% | -25.0% |
| Q1 2020 | $43,000 | -47.6% | 3,126 | +23.5% | 0.00% | -33.3% |
| Q4 2019 | $82,000 | +86.4% | 2,532 | +23.9% | 0.01% | +100.0% |
| Q3 2019 | $44,000 | +1366.7% | 2,044 | +1741.4% | 0.00% | – |
| Q4 2018 | $3,000 | 0.0% | 111 | 0.0% | 0.00% | – |
| Q3 2018 | $3,000 | -92.7% | 111 | -92.6% | 0.00% | -100.0% |
| Q2 2018 | $41,000 | -39.7% | 1,508 | -16.0% | 0.00% | -33.3% |
| Q1 2018 | $68,000 | 0.0% | 1,795 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $68,000 | – | 1,795 | +10458.8% | 0.00% | – |
| Q3 2017 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q2 2017 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | – | 17 | 0.0% | 0.00% | – |
| Q3 2016 | $0 | – | 17 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,295,712 | $47,524,000 | 3.98% |
| Samsara BioCapital, LLC | 232,571 | $3,354,000 | 1.93% |
| Eventide Asset Management | 3,851,000 | $55,531,000 | 1.80% |
| Burrage Capital Management LLC | 112,546 | $1,609,000 | 1.58% |
| Avidity Partners Management LP | 408,000 | $5,883,000 | 0.81% |
| RICE HALL JAMES & ASSOCIATES, LLC | 982,484 | $14,167,000 | 0.79% |
| Bullseye Asset Management LLC | 43,374 | $626,000 | 0.75% |
| Nantahala Capital Management | 1,005,302 | $14,496,000 | 0.54% |
| ARMISTICE CAPITAL, LLC | 600,000 | $8,652,000 | 0.54% |
| Values First Advisors, Inc. | 27,042 | $389,947 | 0.47% |